Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs

Reuters03-31

Liver drug developer Galectin <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' 2025 net loss narrows on reduced R&D costs

Overview

U.S. biotech's 2025 net loss narrowed as R&D expenses declined after NAVIGATE trial end
Company ended 2025 with $17.7 mln cash plus $10 mln credit line, extending runway to April 2027

Outlook

Company expects to fund planned operations and R&D activities through April 2027 with current cash and credit

Result Drivers

R&D COSTS DOWN - Net loss narrowed mainly due to lower research and development expenses after conclusion of NAVIGATE trial

Company press release: ID:nGNXXBl8B

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY EPS		-$0.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623360589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623360589","market":"us","top_or_hot":-1,"title":"Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Liver drug developer Galectin <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' 2025 net loss narrows on reduced R&amp;D costs</title></head><body><p><span>Overview</span></p><ul><li><p>U.S. biotech's 2025 net loss narrowed as R&amp;D expenses declined after NAVIGATE trial end</p></li><li><p>Company ended 2025 with $17.7 mln cash plus $10 mln credit line, extending runway to April 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects to fund planned operations and R&amp;D activities through April 2027 with current cash and credit</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D COSTS DOWN - Net loss narrowed mainly due to lower research and development expenses after conclusion of NAVIGATE trial</p></li></ul><p>Company press release: <span>ID:nGNXXBl8B</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY EPS</p></td><td></td><td><p>-$0.48</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Liver drug developer Galectin <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' 2025 net loss narrows on reduced R&amp;D costs</title></head><body><p><span>Overview</span></p><ul><li><p>U.S. biotech's 2025 net loss narrowed as R&amp;D expenses declined after NAVIGATE trial end</p></li><li><p>Company ended 2025 with $17.7 mln cash plus $10 mln credit line, extending runway to April 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects to fund planned operations and R&amp;D activities through April 2027 with current cash and credit</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D COSTS DOWN - Net loss narrowed mainly due to lower research and development expenses after conclusion of NAVIGATE trial</p></li></ul><p>Company press release: <span>ID:nGNXXBl8B</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY EPS</p></td><td></td><td><p>-$0.48</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL1N40J0HX:1","article_id":"2623360589","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623360589","pubTimestamp":1774958996,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costsOverviewU.S. biotech's 2025 net loss narrowed as R&D expenses declined after NAVIGATE trial endCompany ended 2025 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GALT":"Galectin Therapeutics Inc"},"translate_title":"肝脏药物开发商Galectin Therapeutics 2025年净亏损因研发成本降低而收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GALT":0.9},"content_text":"Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costsOverviewU.S. biotech's 2025 net loss narrowed as R&D expenses declined after NAVIGATE trial endCompany ended 2025 with $17.7 mln cash plus $10 mln credit line, extending runway to April 2027OutlookCompany expects to fund planned operations and R&D activities through April 2027 with current cash and creditResult DriversR&D COSTS DOWN - Net loss narrowed mainly due to lower research and development expenses after conclusion of NAVIGATE trialCompany press release: ID:nGNXXBl8BKey DetailsMetricBeat/MissActualConsensus EstimateFY EPS-$0.48For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623360589","isCrawlerRequest":true}